Chemomab Therapeutics (CMMB) Net Cash Flow Growth (3y) (2020 - 2023)
Chemomab Therapeutics (CMMB) Net Cash Flow Growth (3y) (2020 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 32.17% |
| 10 | Chemomab Therapeutics | 723.35 Mn | 712.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 28.88% |
| Sep 30, 2023 | -50.67% |
| Jun 30, 2023 | -88.26% |
| Mar 31, 2023 | 92.13% |
| Dec 31, 2022 | 35.55% |
| Sep 30, 2022 | 30.61% |
| Jun 30, 2022 | 8.32% |
| Mar 31, 2022 | -27.12% |
| Dec 31, 2021 | -76.68% |
| Sep 30, 2021 | 3.52% |
| Jun 30, 2021 | -38.82% |
| Mar 31, 2021 | 294.82% |
| Dec 31, 2020 | 19.25% |